INTERNATIONAL EXPERIENCE OF ADMINISTRATION OF PACLITAXEL IN TREATMENT OF PATIENTS WITH EARLY BREAST CANCER

The results of different cooperative clinical trials, in which efficiency and safety of the modes of application of Paclitaxel in adjuvant and neoadjuvant chemotherapy of patients with breast cancer (BC), are presented. High efficiency of Paclitaxel is shown in the mode of monotherapy and in combination with other cytostatics and target preparations, including for patients with resistence to antracyclin and for patients with unfavorable prognosis to molecular-genetic subtypes of BC (three times negative, basale, with hyperexpression of Her2/neu). trial. Proc Am Soc Oncol 2004; 23: abstr 719. Frasci G, D’Aiuto G, Comella P, et al. Two-month cisplatin-epirubicin-paclitaxel (PET) weekly administration for the treatment of large operable breast cancer. SICOG 0105 phase II study. Proc Am Soc Clin Oncol 2004; 23: abstr 601.Ponillart P, Fumoleau R, Romieu G, et al. Final results of a phase II randomized parallel study of doxorubicin|cyclophosphamide (AC) and doxorubicin|Taxol (paclitaxel) (AT) as neoadjuvant treatment of local-regional breast cancer. Proc Am Soc Clin Oncol 1999; 18: abstr 275.Fumoleau P, Tubiana-Hulin M, Ronieu G, et al. A randomized study of 4 versus 6 cycles of adriamycin-taxol as neoadjuvant treatment of breast cancer. Breast Cancer Res Treat 2001; 69: 298 (abstr 508).